Sponsor · clinical trials

National University Hospital, Singapore clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our Singapore, Japan, South Korea and Taiwan registers with National University Hospital, Singapore as lead sponsor. Synced 15 Nov 2026

90Current trials

49Recruiting now

58Drugs in these trials

4Trial registers

Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany

Compiled from ClinicalTrials.gov and CTIS registry records · Synced 15 Nov 2026 · Editorial standards

At a glance

National University Hospital, Singapore is the lead sponsor of 90 current clinical trials in our Singapore, Japan, South Korea and Taiwan registers. 49 are recruiting patients now. The most common phase is Not applicable. The drugs named most often in its trials are Bevacizumab, Pembrolizumab and Cyclophosphamide. The most-studied condition is Breast Cancer.

ClinicalTrials.gov trials by status

Recruiting4954%
Not yet open1921%
Active, closed1719%
By invitation56%

Trials by phase

Not applicable4146%
Phase 21314%
Observational1112%
Phase 1/21011%
Phase 189%
Phase 444%
Phase 2/322%
Phase 311%

Clinical trials sponsored by National University Hospital, Singapore

90 on ClinicalTrials.gov

Study	Phase	Status	Start	Registers
ChemoRT With and Without Dental Stent for Taste Protection in NPC Patients NCT06733948 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma	Phase 2	Recruiting	2024-09	Singapore
Liquid Biopsy-Based Pre-Screening to Streamline LDCT Lung Cancer Screening in High-Risk Individuals NCT07358715 · ClinicalTrials.gov ↗ · Lung Cancer, Lung Neoplasms, Early Lung Cancer Detection	Not applicable	Recruiting	2024-11	Singapore
CPAP vs MAD for OSA in Patients With Cognitive Impairment. A Randomized Clinical Trial NCT06983769 · ClinicalTrials.gov ↗ · Obstructive Sleep Apnea (OSA), Mild Cognitive Impairment	Not applicable	Recruiting	2026-01	Singapore
Redirecting Immune, Lipid and Metabolic Drivers of Early Cardiovascular Disease: The RESET Cohort Study NCT06211868 · ClinicalTrials.gov ↗ · Cardiovascular Diseases, Metabolic Syndrome, Non-Alcoholic Fatty Liver Disease	Observational	Recruiting	2024-03	Singapore
A Novel Limb Cryocompression System for Prevention of Chemotherapy Induced Peripheral Neuropathy - Expansion Study NCT05606068 · ClinicalTrials.gov ↗ · Chemotherapy-induced Peripheral Neuropathy	Not applicable	Recruiting	2022-11	Singapore
Alpha Ketoglutarate Enhances Geroprotection In Surgery (AEGIS) NCT07031128 · ClinicalTrials.gov ↗ · CABG	Phase 4	Recruiting	2024-06	Singapore
Discharge Recommendations for Older Adults Using Physical Outcome Measure NCT06903832 · ClinicalTrials.gov ↗ · Discharge Planning, Older Adults (65 Years and Older), Acute Hospitalization	Observational	Recruiting	2025-04	Singapore
Implementation of Decade of Healthy Ageing Action Plan to Screen and Prevent Decline in Intrinsic Capacity in Elders (SPICE) Through Multisectoral Collaboration in Singapore NCT07525583 · ClinicalTrials.gov ↗ · Frailty, Intrinsic Capacity, Lifestyle	Observational	Recruiting	2025-04	Singapore
Cervical Cancer Brachytherapy With Interstitial Needles in 3 Fractions NCT06284031 · ClinicalTrials.gov ↗ · Cervical Cancer	Not applicable	Recruiting	2023-06	Singapore
Potential of Interface Care Models to Deliver More Appropriate Care to Patients With Acute Medical Illness NCT07536035 · ClinicalTrials.gov ↗ · Falls Injury, Falls, Hospitalization in Acute Care	Observational	Recruiting	2024-09	Singapore
Phase I Study of AZD5363 + Olaparib + Durvalumab in Patients With Advanced or Metastatic Solid Tumor Malignancies NCT03772561 · ClinicalTrials.gov ↗ · Solid Tumor, Adult Drugs: Capivasertib, Durvalumab, Olaparib	Phase 1	Recruiting	2018-12	Singapore
Doxycycline Host-directed Therapy to Improve Lung Function and Decrease Tissue Destruction in Pulmonary Tuberculosis NCT05473520 · Tuberculosis, Acute Coronary Syndrome, Pulmonary Hypertension (Diagnosis) Drug: Doxycycline	Phase 3	Recruiting	2023-05	Singapore
The MUSE Study for Menopausal Arthralgia NCT06530459 · ClinicalTrials.gov ↗ · Arthralgia, Menopause, Perimenopausal Disorder	Phase 2/3	Recruiting	2024-08	Singapore
Adjunctive Doxycycline for Central Nervous System Tuberculosis NCT06446245 · ClinicalTrials.gov ↗ · Tuberculosis, Meningeal, Tuberculosis; Meningitis (Etiology), Tuberculosis, Central Nervous System Drug: Doxycycline	Phase 2	Recruiting	2025-08	Singapore
Dupilumab Therapy in Nephrotic Syndrome in Children NCT07091175 · ClinicalTrials.gov ↗ · Nephrotic Syndrome in Children, Nephrotic Syndrome Steroid-Dependent Drug: Dupilumab	Phase 2	Recruiting	2025-11	Singapore
ETC-159 In Combination With Pembrolizumab In Advanced MSS/pMMR Ovarian Cancers NCT06513624 · ClinicalTrials.gov ↗ · With MSS/pMMR Advanced, Platinum-resistant Ovarian Cancer Drug: Pembrolizumab	Phase 1	Recruiting	2024-12	Singapore
Use of a Digital Psychotherapeutic App to Reduce Symptom Burden in Dermatology Patients NCT06702293 · ClinicalTrials.gov ↗ · Eczema, Psoriasis, Urticaria	Not applicable	Recruiting	2026-02	Singapore
Sacituzumab Govitecan in Metastatic Salivary Gland and Thyroid Cancers (SG-SGTC) NCT06923826 · ClinicalTrials.gov ↗ · Salivary Gland Cancer, Thyroid Cancer Drug: Sacituzumab Govitecan	Phase 2	Recruiting	2025-04	Singapore
Singapore Perioperative Ageing Study (Sing-PAS) NCT04792554 · ClinicalTrials.gov ↗ · Postoperative Delirium, Aging, Myocardial Injury	Observational	Recruiting	2021-04	Singapore
Mepitel Film Breast NCT07729423 · Breast Cancer, Radiation Dermatitis	Observational	Recruiting	2025-11	Singapore
A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced Cancers NCT06422403 · ClinicalTrials.gov ↗ · Carcinoma, Hepatocellular, Gastric Adenocarcinoma, GastroEsophageal Cancer	Phase 2	Recruiting	2024-11	Singapore
Evaluation of ex Vivo Drug Combination Optimization Platform in Recurrent High Grade Astrocytic Glioma NCT05532397 · ClinicalTrials.gov ↗ · Glioma, Astrocytic	Not applicable	Recruiting	2023-02	Singapore
Antigen Targeted T Cell Therapy for Relapsed/Refractory B Cell Lymphomas NCT07319676 · ClinicalTrials.gov ↗ · B-cell Lymphoma Refractory	Phase 1/2	Recruiting	2026-03	Singapore
Reducing Delirium After CABG Surgery With Early Activation and Sleep-Promoting Routines NCT06107517 · ClinicalTrials.gov ↗ · Delirium, Postoperative	Not applicable	Recruiting	2024-01	Singapore
Antenatal Myo-inositol Supplementation in Pre-existing Diabetes NCT07241221 · ClinicalTrials.gov ↗ · Perinatal and Neonatal Outcomes in Pregnancies With Type 2 Diabetes Mellitus (T2DM)	Not applicable	Recruiting	2025-12	Singapore
StrataXRT vs Standard Clinical Practice for the Prevention of Acute Dermatitis in Head and Neck Cancers Patients NCT03394417 · ClinicalTrials.gov ↗ · Head and Neck Cancers, Acute Radiation Dermatitis	Not applicable	Recruiting	2018-11	Singapore
Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START) NCT05035745 · ClinicalTrials.gov ↗ · Advanced Refractory Solid Tumors, Advanced Triple Negative Breast Cancers, Metastatic Triple Negative Breast Cancers Drugs: Selinexor, Talazoparib	Phase 1/2	Recruiting	2021-03	Singapore
NEUROprotection Via optimizINg Cerebral Blood Flow afTer cArdiaC arresT (NEURO-INTACT) Study NCT05679739 · Out-Of-Hospital Cardiac Arrest (OHCA)	Not applicable	Recruiting	2023-08	Singapore
Pulsed Electromagnetic Fields in Preventing Physical Deconditioning in Patients Undergoing Prolonged Hospitalization NCT06744764 · ClinicalTrials.gov ↗ · Haematological Cancer, Healthy	Not applicable	Recruiting	2023-04	Singapore
Effectiveness of Pulpotomy vs. Root Canal Treatment in Extremely Deep Caries NCT07242742 · ClinicalTrials.gov ↗ · Extremely Deep Caries, Pulpitis	Not applicable	Recruiting	2025-07	Singapore
Evaluating Different Protocols of Non-invasive Brain Stimulation (NIBS) in Stroke Rehabilitation NCT07786649 · ClinicalTrials.gov ↗ · Stroke	Not applicable	Recruiting	2024-08	Singapore
Single Centre Prospective Evaluation of 68Gallium-FAPI PET/MRI in Hepatocellular Carcinoma NCT05687747 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma	Phase 1	Recruiting	2023-08	Singapore
Lenvatinib+Letrozole Versus Fulvestrant in Metastatic ER+/HER2- Breast Cancer, Post Progression on Al + CDK4/6 Inhibitor NCT05181033 · ClinicalTrials.gov ↗ · Breast Cancer Drugs: Fulvestrant, Lenvatinib, Letrozole	Phase 2	Recruiting	2021-12	Singapore
Optimizing and Personalising Azacitidine Combination Therapy for Treating Solid Tumours QPOP and CURATE.AI NCT05381038 · ClinicalTrials.gov ↗ · Solid Tumor, Gastrointestinal Cancer, Breast Cancer Drugs: Azacitidine, Docetaxel, Irinotecan	Phase 1/2	Recruiting	2023-02	Singapore
Developing and Testing the Effectiveness of a Skin Cancer Self-Detection Educational Program NCT07247123 · ClinicalTrials.gov ↗ · Skin Cancer, Skin Cancer Prevention, Benign Skin Growth	Not applicable	Recruiting	2026-06	Singapore
Neural Network-based Treatment Decision Support Tool in Patients With Refractory Solid Organ Malignancies NCT05719428 · ClinicalTrials.gov ↗ · Solid Organ Malignancies	Phase 2	Recruiting	2023-08	Singapore
tSCS + UL Robotics Training in SCI Patients NCT07432321 · ClinicalTrials.gov ↗ · Spinal Cord Injuries	Not applicable	Recruiting	2025-09	Singapore
Multimodal Prehabilitation in Gastric Cancer Patients NCT07839702 · ClinicalTrials.gov ↗ · Gastric Cancer (GC), Prehabilitation, Postoperative Inflammation	Not applicable	Recruiting	2026-07	Singapore
Randomised Trial of Induction Gemcitabine and Cisplatin Versus Gemcitabine, Cisplatin, Pembrolizumab and Bevacizumab (GPPB) in Nasopharyngeal Cancer NCT05305131 · ClinicalTrials.gov ↗ · Nasopharyngeal Cancer	Phase 2	Recruiting	2022-03	Singapore
Neoadjuvant ADG126 and Pembrolizumab in Locally Advanced Colorectal Cancer NCT06846268 · ClinicalTrials.gov ↗ · Locally Advanced Colorectal Cancer Drugs: ADG126, Keytruda, Pembrolizumab	Phase 2	Recruiting	2025-04	Singapore
PREcision MApping and NEuromodulation After Spontaneous Intracerebral Hemorrhage: The PREMANE Trial NCT07908264 · ClinicalTrials.gov ↗ · Spontaneous Intracerebral Hemorrhage	Not applicable	Recruiting	2026-08	Singapore
Osimertinib for Advanced EGFR-positive NSCLC Patients NCT05037331 · ClinicalTrials.gov ↗ · EGFR Positive Non-small Cell Lung Cancer, Non Small Cell Lung Cancer	Observational	Recruiting	2021-07	Singapore
Pembrolizumab and ADG106 in Advanced Solid Cancers and Triple Negative Breast Cancer NCT05491083 · ClinicalTrials.gov ↗ · Advanced Solid Tumor, Triple Negative Breast Cancer	Phase 1/2	Recruiting	2023-06	Singapore
Screening for Early Diagnosis of Nose Cancer NCT07019870 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma	Not applicable	Recruiting	2022-11	Singapore
Study on the Effect of Atorvastatin Co-administered With Omeprazole on Statin Lactone NCT06690164 · Metabolite Drugs: Atorvastatin, Omeprazole	Phase 4	Recruiting	2025-06	Singapore
Compliance With Standard Care vs Ready to Eat Meals Prior to Bariatric Surgery NCT06461247 · ClinicalTrials.gov ↗ · Bariatric Surgery Candidate	Not applicable	Recruiting	2024-07	Singapore
Study of EGFR TKI in Patients With Advanced NSCLC Harbouring EGFR Mutations NCT06062823 · ClinicalTrials.gov ↗ · NSCLC Drugs: Afatinib, Gilotrif	Phase 2	Recruiting	2024-03	Singapore
Ma-Spore ALL 2020 Study NCT06336395 · ClinicalTrials.gov ↗ · B Lymphoblastic Leukemia Drugs: Cyclophosphamide, Cytarabine, Dasatinib	Phase 2	Recruiting	2020-03	Singapore
Transcutaneous Spinal Cord Stimulation With Robotic Gait Training in Chronic SCI NCT05921175 · Spinal Cord Injury	Not applicable	Recruiting	2024-11	Singapore
Evaluating the Optimal Timing of Acupuncture for Managing Chemoradiation-induced Xerostomia in Patients With Head and Neck Cancers NCT07674706 · ClinicalTrials.gov ↗ · Xerostomia, Head Cancer, Neck Cancer	Not applicable	Not yet open	2026-06	Singapore
Pioneering Advancements in Cardiocerebrovascular Interactions in the Asia pacFIC - Patent Foramen Ovale Study NCT06983795 · ClinicalTrials.gov ↗ · Ischemic Stroke, Patent Foramen Ovale Drugs: Cilostazol, Clopidogrel, Dipyridamole	Observational	Not yet open	2025-07	Singapore
Tislelizumab in Combination With Bevacizumab and Capecitabine in Advanced Solid Tumors With Evaluation in Immunotherapy-Resistant and Central Nervous System Disease NCT07681297 · Advanced Solid Tumor Cancer, Triple-Negative Breast Cancer (TNBC), CNS Disease Drugs: Bevacizumab, Capecitabine, Tislelizumab	Phase 1/2	Not yet open	2026-08	Singapore
Combined rTMS and tSCS for Upper Limb Recovery in Cervical SCI NCT07586644 · Spinal Cord Injuries (SCI)	Not applicable	Not yet open	2027-03	Singapore
Combined TMS-tSCS for Lower Limb Rehabilitation in Chronic Incomplete SCI NCT07595497 · ClinicalTrials.gov ↗ · Spinal Cord Injuries (SCI)	Not applicable	Not yet open	2027-01	Singapore
Use of Pyrvinium to Reverse Stomach Precancerous Conditions NCT06782048 · ClinicalTrials.gov ↗ · STOMACH NEOPLASM	Phase 2	Not yet open	2026-11	Singapore
Evaluating Ivonescimab in PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma NCT07565389 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma (NPC) Drug: Ivonescimab	Phase 2	Not yet open	2026-05	Singapore
TTNS in SCI Patients With Neurogenic Detrusor Overactivity NCT07785258 · ClinicalTrials.gov ↗ · Spinal Cord Injuries, Neurogenic Detrusor Overactivity	Not applicable	Not yet open	2026-09	Singapore
Early Screening for Gestational Diabetes Mellitus in a Low Risk Population NCT06704035 · ClinicalTrials.gov ↗ · Gestational Diabetes Mellitus (GDM), Glucose Intolerance During Pregnancy	Not applicable	Not yet open	2024-12	Singapore
Mandibular Advancement to Reduce Ventricular Load and Improve Quality-of-life in Heart Failure NCT07460505 · Heart Failure, OSA - Obstructive Sleep Apnea	Not applicable	Not yet open	2026-05	Singapore
AI-Powered CURAᵀᴹ Application for Identifying At-Risk Pregnancies in Obstetric Management NCT06974188 · ClinicalTrials.gov ↗ · High-risk Pregnancy, Pregnancy, Antenatal Health	Not applicable	Not yet open	2025-08	Singapore
Comparing Effectiveness of Steroids and Methotrexate in Treatment of Chronic Inflammatory Breast Disease NCT06943482 · ClinicalTrials.gov ↗ · Idiopathic Granulomatous Mastitis Drugs: Folic Acid, Methotrexate, Omeprazole	Phase 4	Not yet open	2025-07	Singapore
Implementation Study on Hospital-to-home Advanced Rehabilitation Technologies (ART) NCT07904624 · ClinicalTrials.gov ↗ · Brain Injuries	Not applicable	Not yet open	2026-11	Singapore
Mapping the Neural Circuits of Depression and Anxiety Using Personalized, Accelerated TMS and Deep Phenotyping NCT07766291 · Depression Disorder	Not applicable	Not yet open	2026-09	Singapore
Study of MC001 in Patients With Advanced Solid Tumours NCT07929961 · ClinicalTrials.gov ↗ · Pancreatic Ductal Adenocarcinoma (PDAC), Nasopharyngeal Carcinoma, Advanced Solid Tumours Drug: MC001	Phase 1	Not yet open	2026-11	Singapore
Maintenance Individualized Neuromodulation and Depression-detection Via Sensors for Early Treatment NCT07779330 · ClinicalTrials.gov ↗ · Depression Disorder	Not applicable	Not yet open	2026-09	Singapore
Personalized and Accelerated Transcranial Magnetic Stimulation for Treatment-resistant Anxiety Related Disorders NCT07801391 · ClinicalTrials.gov ↗ · Anxiety and Fear-Related Disorders	Not applicable	Not yet open	2026-09	Singapore
tACS and Upper Limb Rehabilitation in Chronic Stroke NCT07778342 · ClinicalTrials.gov ↗ · Stroke	Not applicable	Not yet open	2026-12	Singapore
Lifescapes System in Post-stroke Hand Recovery NCT07784920 · ClinicalTrials.gov ↗ · Stroke	Not applicable	Not yet open	2026-10	Singapore
Community Study to Increase Mammogram Screening Among Overdue Women NCT07832396 · ClinicalTrials.gov ↗ · This Study Evaluates Interventions to Increase Surveillance Mammography Uptake for Early Breast Cancer Detection Among Singaporean Women in Real World	Not applicable	By invitation	2026-11	Singapore
Trial to Evaluate the Impact of Various Pragmatic Interventions to Increase Mammography Uptake Among Defaulted Repeat Screeners in Singapore NCT07651345 · ClinicalTrials.gov ↗ · Mammogram Uptake, Breast Cancer, Breast Neoplasm	Not applicable	By invitation	2026-03	Singapore
Trial to Evaluate the Impact of Various Behavioural Interventions to Increase Mammography Uptake Among Singaporean Women NCT07283107 · ClinicalTrials.gov ↗ · This Study Evaluates Interventions to Increase Surveillance Mammography Uptake for Early Breast Cancer Detection Among Singaporean Women	Not applicable	By invitation	2025-11	Singapore
Pulpotomy vs Root Canal Treatment for Teeth With Symptomatic Irreversible Pulpitis NCT05964933 · ClinicalTrials.gov ↗ · Pulpitis - Irreversible	Not applicable	By invitation	2023-07	Singapore
Pragmatic Mobile Health Trial to Promote Cancer Screening and Healthy Behaviors NCT07725328 · ClinicalTrials.gov ↗ · Cancer Screening, Chronic Diseases in Older Adults, Early Cancer Detection	Not applicable	By invitation	2027-01	Singapore
A First-in-Human Study of PRL3-ZUMAB NCT03191682 · Advanced Solid Tumors Drug: PRL3-ZUMAB	Phase 1	Active, closed	2017-02	Singapore
Neoadjuvant Lenvatinib Combined With Letrozole in Hormone Receptor Positive Breast Cancer NCT02562118 · ClinicalTrials.gov ↗ · Breast Cancer Drugs: Lenvatinib, Letrozole	Phase 1/2	Active, closed	2015-10	Singapore
Bevacizumab and Pembrolizumab Combination in Platinum-resistant Recurrent/Metastatic NPC NCT03813394 · Locally Recurrent Cancer, Metastatic Nasopharyngeal Cancer Drugs: Bevacizumab, Pembrolizumab	Phase 1/2	Active, closed	2019-05	Singapore
Validation of a Molecular Test for Risk-stratification of Patients With High-risk Intestinal Metaplasia (GCEP2 Study) NCT05782465 · ClinicalTrials.gov ↗ · Stomach Neoplasm	Observational	Active, closed	2019-08	Japan, South Korea, Taiwan, Singapore
To Create an Artificial Intelligence-enabled Device for Airway Assessment (AINFAS) to Identify Patients With Difficult Airway Pre-operatively. NCT07411495 · ClinicalTrials.gov ↗ · Anaesthesia	Observational	Active, closed	2022-05	Singapore
Establishing a Prognostic Model for Stroke Recovery NCT05332652 · ClinicalTrials.gov ↗ · Stroke, Acute	Not applicable	Active, closed	2020-09	Singapore
Root Canal Treatment With TotalFill® Bioceramic Sealer and AH Plus® Sealer NCT03732170 · ClinicalTrials.gov ↗ · Root Canal Obturation	Not applicable	Active, closed	2018-08	Singapore
Conversion Surgery for Gastric Cancer With Peritoneal Metastases (CONVERGENCE) NCT07241715 · ClinicalTrials.gov ↗ · Gastric Cancer Stage IV, Peritoneal Metastasis	Phase 2/3	Active, closed	2026-02	Singapore
Hyperbaric Bupivacaine Versus Hyperbaric Prilocaine in Spinal Anaesthesia NCT07329582 · ClinicalTrials.gov ↗ · Knee Replacement, Total, Knee Replacement Surgery Drugs: Bupivacaine, Prilocaine	Phase 4	Active, closed	2024-05	Singapore
Phase II Study of FTD/TPI (Lonsurf) in Metastatic Breast Cancers With or Without Prior Exposure to Fluoropyrimidines (LONBRECA) NCT04280536 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 1/2	Active, closed	2019-08	Singapore
A Pilot Study of Ciprofloxacin Plus Gemcitabine and Nab-Paclitaxel Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma. NCT04523987 · ClinicalTrials.gov ↗ · Metastatic Pancreatic Ductal Adenocarcinoma Drug: Ciprofloxacin	Phase 1	Active, closed	2019-02	Singapore
A Phase Ib Safety lead-in, Followed by Phase II Trial of ADG106 in Combination With Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer NCT05275777 · ClinicalTrials.gov ↗ · HER2-negative Breast Cancer, Advanced Solid Tumor Drugs: Adriamycin, Cyclophosphamide, Doxorubicin	Phase 1/2	Active, closed	2022-05	Singapore
Comparison of Pacing Lead Design on Left Bundle Branch Pacing Outcomes: The LEAD_LBBP Randomized Clinical Trial NCT06318130 · ClinicalTrials.gov ↗ · Pacemaker DDD	Not applicable	Active, closed	2023-01	Singapore
Safety Of Nrtis for Alzheimer's Therapeutic Advancement in Singapore Study NCT07210528 · ClinicalTrials.gov ↗ · Mild Cognitive Impairment (MCI), Alzheimer Dementia (AD) Drugs: Descovy, Emtricitabine, TAF/FTC	Phase 1	Active, closed	2025-06	Singapore
A Single Arm, Phase Ib/II Trial of Single Agent Pacritinib in Patients With 1q21.3 Amplified Solid Tumors Enriching for Interleukin-1 Receptor-associated Kinase 1 Pathway Activation (PAIR) NCT04520269 · ClinicalTrials.gov ↗ · Breast Cancer Drug: Pacritinib	Phase 1/2	Active, closed	2020-07	Singapore
Phase I Study of RNA Oligonucleotide, MTL-CEBPA, Atezolizumab and Bevacizumab in Patients With Advanced Hepatocellular Carcinoma. NCT05097911 · ClinicalTrials.gov ↗ · Advanced Hepatocellular Carcinoma Drugs: Atezolizumab, Bevacizumab	Phase 1	Active, closed	2021-08	Singapore
Growing Up in Singapore Towards Healthy Outcomes NCT01174875 · ClinicalTrials.gov ↗ · Metabolic Diseases, Neurological and Mental Health Conditions, Genetic Predisposition	Observational	Active, closed	2009-06	Singapore

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

Drugs in National University Hospital, Singapore trials

58 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

+ 18 more in the trial list above.

Conditions in National University Hospital, Singapore trials

146 conditions

Breast Cancer8 Nasopharyngeal Carcinoma3 Stroke3 Nasopharyngeal Carcinoma (NPC)2Cancer Screening2Spinal Cord Injuries (SCI)2Spinal Cord Injuries2Depression Disorder2Advanced Solid Tumor2Stomach Neoplasm1Advanced Solid Tumors1Xerostomia1Head Cancer1Neck Cancer1Ischemic Stroke1Patent Foramen Ovale1Lung Cancer1 Lung Neoplasms1Early Lung Cancer Detection1Advanced Solid Tumor Cancer1Triple-Negative Breast Cancer (TNBC)1CNS Disease1Obstructive Sleep Apnea (OSA)1Mild Cognitive Impairment1

By trial register

Register	Trials	Recruiting
Clinical trials in Singapore	90	49
Clinical trials in Japan	1	0
Clinical trials in South Korea	1	0
Clinical trials in Taiwan	1	0

A trial with sites in more than one country appears in each of those registers.

Other sponsors in Breast Cancer

Sponsor	Trials
Fudan University	50
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	21
AstraZeneca	18
Second Affiliated Hospital, Zhejiang University, School of Medicine	18
University Health Network, Toronto	16
Institut du Cancer de Montpellier - Val d'Aurelle	16
Sunnybrook Health Sciences Centre	15
Shengjing Hospital	15
European Institute of Oncology	14
Pfizer	12

Sponsors with the most current trials registered for this condition.

Questions about National University Hospital, Singapore trials

How many clinical trials does National University Hospital, Singapore sponsor?

National University Hospital, Singapore is the lead sponsor of 90 current trials on ClinicalTrials.gov in our Singapore, Japan, South Korea and Taiwan registers, as of the registry sync on 15 November 2026. Completed and withdrawn studies are not counted.

Are National University Hospital, Singapore trials recruiting?

Yes. 49 of its 90 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is National University Hospital, Singapore testing?

Its current trials name 58 drugs and biologicals as interventions. The most frequent are Bevacizumab (3), Pembrolizumab (3), Cyclophosphamide (2), Doxorubicin (2) and Doxycycline (2). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 15 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.